Senores Pharmaceuticals Limited has informed the Exchange regarding updates on USFDA Inspection at Havix Group Inc. d/b/a Aavis Pharmaceuticals, material subsidiary of the Company
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals has informed the exchange about an update regarding a USFDA inspection conducted at its material subsidiary, Havix Group Inc. (doing business as Aavis Pharmaceuticals). The subsidiary is based in the US and is a significant part of the company's operations. The filing pertains to the outcome or status of this regulatory inspection by the US drug regulator. Specific details of the inspection findings or classification (such as Form 483 observations or EIR) are not provided in the headline. The exchange has been formally notified as part of ongoing disclosure obligations.
USFDA inspection outcomes can significantly impact a pharma company's revenue and stock price if adverse findings lead to warning letters or import alerts. Shareholders should watch for further details on the inspection classification and any potential supply disruptions from the subsidiary.